<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833205</url>
  </required_header>
  <id_info>
    <org_study_id>BH005</org_study_id>
    <nct_id>NCT04833205</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer</brief_title>
  <official_title>Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui Bu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of&#xD;
      Leptomeningeal Metastases From Lung Cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 19, 2021</start_date>
  <completion_date type="Anticipated">April 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>From the diagnosis of the LM to the time of disease worsen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>From the diagnosis of theLM to the time of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>8Weeks</time_frame>
    <description>When the Nimotuzumab is used,we will observe if the patients have the allergic reaction,diarrhea ,vomiting and so on.Number of participants with treatment-related adverse events as assessed by CTCAE v4.0&quot;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leptomeningeal Metastasis</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Leptomeningeal metastases received EGFR-TKI and Nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients received Nimotuzumab 200 mg,which was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping.And the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks.One the other hand,the patient received the third generation of EGFR-TKI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks</description>
    <arm_group_label>Leptomeningeal metastases received EGFR-TKI and Nimotuzumab</arm_group_label>
    <other_name>EGFR-TKI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 years or older, gender not limited;&#xD;
&#xD;
          -  A definite diagnosis of Leptomeningeal metastases from lung cancer, including&#xD;
             cerebrospinal fluid cytology and/or neuroimaging;&#xD;
&#xD;
          -  Have a clear history of lung cancer, including histopathological diagnosis, or&#xD;
             cytopathology combined with imaging diagnosis&#xD;
&#xD;
          -  Patients who received any of EGFR inhibitors (gefitinib, erlotinib, afatinib,&#xD;
             osimertinib etc.) meet the diagnostic criteria for secondary resistance and were in a&#xD;
             slow progression stage&#xD;
&#xD;
          -  Detection results of cerebrospinal fluid, blood gene or lung tissue specimens showed&#xD;
             EGFR mutation, and immunohistochemistry results of cerebrospinal fluid, blood gene or&#xD;
             lung tissue showed positive EGFR expression&#xD;
&#xD;
          -  Bone marrow, liver, kidneys and blood clotting function are relatively stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group scored &gt; 2 points&#xD;
&#xD;
          -  Patients had poor compliance, or for other reasons the investigator considered them&#xD;
             unsuitable to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jiao xue qi, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hui bu, PhD</last_name>
    <phone>0311-66003711-211</phone>
    <email>buhuimy1@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jiao xue qi, master</last_name>
    <email>1074234012@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Hebei</city>
        <state>Shijiazhuang/hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hui bu, phd</last_name>
      <phone>13831106903</phone>
      <email>buhuimy1@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Hebei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hui bu, phD</last_name>
      <phone>13831106903</phone>
      <email>buhuimy1@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 18, 2021</last_update_submitted>
  <last_update_submitted_qc>April 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Hui Bu</investigator_full_name>
    <investigator_title>The department of neurology,clincial professor,director</investigator_title>
  </responsible_party>
  <keyword>Leptomeningeal Metastasis</keyword>
  <keyword>,Nimotuzumab</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>EGFR-TKI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

